ZVRA Earnings

ZVRA reported its earnings on 2026-03-09, showcasing a revenue of 34.13M against an estimate of 27.91M, resulting in a 22.27% surprise. The EPS was 1.16, surpassing the expected 0.04 by 2800%. The stock experienced a 21.27% price change on the earnings day and a 9.43% change over the next five days, reflecting market reactions to the results.

Following ZVRA's earnings announcement on 2026-03-09, the stock price moved by 21.27% on the day of the release. Over the subsequent five days, it saw a 9.43% change. Historically, ZVRA's stock price tends to shift by an average of -5.76% in the 10 days leading up to earnings and -3.78% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate ZVRA's annual revenue to reach 32.25M, while the EPS is projected at 0.10. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ZVRA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ZVRA's stock price typically moves by -5.76% in the 10 days before its earnings and -3.78% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.10 and revenue of 32.25M.

The earnings call highlights strong financial health with improved net loss, a solid cash position, and manageable debt. The European market expansion and patent extension efforts indicate growth potential. The Q&A session reveals optimism about new patient growth and strategic collaborations, despite some uncertainties. The positive sentiment is bolstered by successful disease awareness campaigns and partnerships. However, variability in sales and lack of specific guidance on some metrics may temper immediate expectations. Overall, the sentiment leans positive, suggesting a likely stock price increase within the 2% to 8% range.